Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.60 |
| ▸ | MAOA | P21397 | 2/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2617233 | 1.00 | TAAR1 (0.61) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| SCHEMBL2617234 | 1.00 | TAAR1 (0.61) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydrochloric Acid SCHEMBL17674512 | 0.98 | TAAR1 (0.59) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydrochloric Acid SCHEMBL30559541 | 0.98 | TAAR1 (0.59) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| SCHEMBL10872752 | 0.87 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| SCHEMBL10872755 | 0.87 | TAAR1 (0.76) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| SCHEMBL10525345 | 0.86 | TAAR1 (0.47) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydrochloric Acid SCHEMBL4683910 | 0.80 | CYP2D6 (0.61) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| SCHEMBL3672157 | 0.80 | TAAR1 (0.48) | TAAR1SLC6A4MAOACYP2A6 | |
| SCHEMBL10775150 | 0.80 | TAAR1 (0.67) | TAAR1SLC6A2SLC6A3SLC6A4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340587-A1 | INSOLUBLE SUPPORT FOR SOLID PHASE SYNTHESIS | POLYPEPTIDE LABORATORIES HOLDING PPL AB (SE) | 2025-11-06 | — | — | US | claimed |
| CN-119678852-A | Breeding method for excellent seedlings of dendrobium nobile in tropical rain forest | 海南乾景越实业集团有限公司 | 2025-03-25 | — | — | CN | claimed |
| EP-4444283-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2024-10-16 | — | — | EP | claimed |
| CN-118526582-A | Bioorthogonal chemical method for activating active molecules by infrared remote control | 北京大学 | 2024-08-23 | — | — | CN | claimed |
| CN-117486960-A | Preparation method of cholesterol and intermediate thereof | 苏州保尔朴生物医药科技有限公司 | 2024-02-02 | — | — | CN | claimed |
| WO-2023107715-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | claimed |
| CN-114315947-A | Novel method for synthesizing cholesterol and 25-hydroxycholesterol by using 22-sterol as raw material | 上海敏韬医药科技有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-111777540-A | Method for synthesizing pyrrolidone compound by continuous light-induced catalysis | 南京工业大学 | 2020-10-16 | — | — | CN | claimed |
| WO-2019200940-A1 | PEROVSKITE THIN FILM AND PREPARATION METHOD THEREFOR, PEROVSKITE ELECTROLUMINESCENT DEVICE AND PREPARATION METHOD THEREFOR, AND DISPLAY DEVICE | 京东方科技集团股份有限公司 | 2019-10-24 | — | — | WO | claimed |
| CN-122032659-A | Modified macroporous strong alkali anion resin and preparation method and application thereof | 中国科学院青海盐湖研究所 | 2026-05-15 | — | — | CN | disclosed |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | Ensysce Biosciences Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4720038-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20260048567-A1 | METHOD, DECORATIVE FILM AND HIGH-PERFORMANCE COATING FOR DECORATING AND EMBOSSING A MATERIAL | MACOR GIORGIO (IT) | 2026-02-19 | — | — | US | disclosed |
| EP-4683622-A1 | NON-DISTILLATIVE PROCESS FOR MANUFACTURING HIGH PURITY AMPHETAMINES | Pharmapotheca A, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-0507863-A4 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | — | 1993-07-07 | — | — | EP | disclosed |
| WO-1993000313-A2 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-01-07 | — | — | WO | disclosed |
| EP-0507863-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1992-10-14 | — | — | EP | disclosed |
| WO-1991009594-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1991-07-11 | — | — | WO | disclosed |
| US-4857553-A | SIDE EFFECT REDUCTION | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-08-15 | — | — | US | disclosed |
| EP-0302757-A2 | Anti-emetic serotonin depleting agents | A.H. ROBINS COMPANY, INCORPORATED (US) | 1989-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340587-A1 | INSOLUBLE SUPPORT FOR SOLID PHASE SYNTHESIS | SSU72, CPSF6, IDUA | TAAR1 2604/4885SLC6A2 4020/4885SLC6A3 3673/4885 |
| US-20260048567-A1 | METHOD, DECORATIVE FILM AND HIGH-PERFORMANCE COATING FOR DECORATING AND EMBOSSING A MATERIAL | EMD, LIN28A, TMPO | TAAR1 1354/4885SLC6A2 1452/4885SLC6A3 2184/4885 |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | OPRK1, OPRL1, OPRM1 | TAAR1 543/4885SLC6A2 1385/4885SLC6A3 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.